Molecular evaluation of human papillomavirus as an oncogenic biomarker in prostate cancer.
Human papillomavirus
Moroccan population
PCR
Prostate cancer (PCa)
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
19
01
2023
accepted:
18
04
2023
medline:
26
6
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
Prostate cancer (PCa) is one of the most common tumors in men, regardless of ethnicity and demographics. In many risk factors causing PCa, genes and viral infections are strong candidates for the development of prostate tumors. Indeed, tissue infections of PCa have been reported by the presence of several types of viruses including Human Papillomaviruses (HPV). the present study was planned to determine whether HPV DNA could be detected in the blood of known men with prostate cancer and to assess the potential association between HPV infection and clinico-pathological characteristics of the patients. In order to achieve our objectives, 150 liquid blood samples were taken from Moroccan patients, 100 patients with PCa, and 50 control cases. The viral DNA was extracted, calibrated and the target genes were amplified by PCR using specific primers and the use of 2% agarose gel with visualization under UV. Of the 100 samples tested, (10%) were infected with HPV), However, none of the control cases were infected with HPV. The analysis of the data made it possible to establish a correlation between the frequency of the viral infection of the human papilloma and the tumoral criteria. Therefore, this study strengthens the potential role of HPV as a cofactor in prostate cancer development, and we propose that infection with this virus may be involved in the development of PCa metastases.
Sections du résumé
BACKGROUND
BACKGROUND
Prostate cancer (PCa) is one of the most common tumors in men, regardless of ethnicity and demographics. In many risk factors causing PCa, genes and viral infections are strong candidates for the development of prostate tumors. Indeed, tissue infections of PCa have been reported by the presence of several types of viruses including Human Papillomaviruses (HPV).
OBJECTIVE
OBJECTIVE
the present study was planned to determine whether HPV DNA could be detected in the blood of known men with prostate cancer and to assess the potential association between HPV infection and clinico-pathological characteristics of the patients.
MATERIALS AND METHODS
METHODS
In order to achieve our objectives, 150 liquid blood samples were taken from Moroccan patients, 100 patients with PCa, and 50 control cases. The viral DNA was extracted, calibrated and the target genes were amplified by PCR using specific primers and the use of 2% agarose gel with visualization under UV.
RESULTS
RESULTS
Of the 100 samples tested, (10%) were infected with HPV), However, none of the control cases were infected with HPV. The analysis of the data made it possible to establish a correlation between the frequency of the viral infection of the human papilloma and the tumoral criteria.
CONCLUSION
CONCLUSIONS
Therefore, this study strengthens the potential role of HPV as a cofactor in prostate cancer development, and we propose that infection with this virus may be involved in the development of PCa metastases.
Identifiants
pubmed: 37217619
doi: 10.1007/s11033-023-08474-6
pii: 10.1007/s11033-023-08474-6
doi:
Substances chimiques
DNA, Viral
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5719-5724Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Reza MA, Fahimeh G, Reza MH (2012) Evaluation of xenotropic murine leukemia virus and its R426Q polymorphism in patients with prostate cancer in Kerman, southeast of Iran. Asian Pac J Cancer Prev 13:3669–3673
doi: 10.7314/APJCP.2012.13.8.3669
pubmed: 23098452
Stolten M, Ledet E, Dotiwala A et al (2015) Alternative digit ratios and their relationship to prostate Cancer. Clin Genitourin Cancer 14:149–152
doi: 10.1016/j.clgc.2015.11.005
pubmed: 26684813
Humphrey PA (2017) Histopathology of prostate Cancer. ColdSpring _ Harb Prospect Med 7:a030411
doi: 10.1101/cshperspect.a030411
Inamura K (2018) Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget 9:14723–14737
doi: 10.18632/oncotarget.24515
pubmed: 29581876
pmcid: 5865702
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
Abumsimir B, Kasmi Y, Ennaji MM (2019) Rereading of the genetics origins of cancer: the puzzle of all eras. PeerJ Preprints 7:e27952v1
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
Lehaire J (2016) Detection and characterization of prostate cancer by multiparametric 1.5 T MRI images (Doctoral dissertation, University of Lyon)
Sfanos KS, De Marzo AM (2012) Prostate cancer and inflammation: the evidence. Histopathology 60:199–215
doi: 10.1111/j.1365-2559.2011.04033.x
pubmed: 22212087
pmcid: 4029103
Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Peña AT, …, Ward AB (2014) Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 env trimers. Immunity 40(5):669–680
doi: 10.1016/j.immuni.2014.04.008
pubmed: 24768348
pmcid: 4057017
Yang J, Zhang Y (2015) Protein structure and function prediction using I-TASSER. Curr protocols Bioinf 52(1):5–8
doi: 10.1002/0471250953.bi0508s52
Bae K, Kang G, Cho SK, Park W, Kim K, Padilla WJ (2015) Flexible thin-film black gold membranes with ultrabroadband plasmonic nanofocusing for efficient solar vapour generation. Nat Commun 6(1):1–9
doi: 10.1038/ncomms10103
Sadri Nahand J, Moghoofei M, Salmaninejad A, Bahmanpour Z, Karimzadeh M, Nasiri M, …, Hamblin MR (2020) Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. Int J Cancer 146(2):305–320
doi: 10.1002/ijc.32688
pubmed: 31566705
Moore PS, Chang Y (2010) Why do viruses cause cancer? Highlights of the first century of human tumor virology. Nat Rev Cancer 10:878–889
doi: 10.1038/nrc2961
pubmed: 21102637
pmcid: 3718018
Moghoofei M, Mostafaei S, Nesaei A, Etemadi A, Sadri Nahand J, Mirzaei H et al (2019) Epstein–Barr virus and thyroid cancer: the role of viral expressed protein. J Cell Physiol 234:3790–3799
doi: 10.1002/jcp.27144
pubmed: 30362517
Blaylock RL (2019) Viruses and tumor cell microenvironment: a brief summary.Surgical neurology international, 10
Mostafaei S, Keshavarz M, Nahand JS, Hassankiadeh RF, Moradinazar M, Nouri M et al (2020) Viral infections and risk of thyroid cancer: a systematic review and empirical bayesian meta-analysis. Pathology-Research and Practice 216:152855
doi: 10.1016/j.prp.2020.152855
pubmed: 32111443
Taylor ML, Mainous AG 3rd, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. FamMed 37:506–512
Sutcliffe S et al (2011) Prostate involvement during sexually transmitted infections as measured by prostate - specific antigen concentration. Br J Cancer 105:602–605
doi: 10.1038/bjc.2011.271
pubmed: 21792196
pmcid: 3188942
Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527
doi: 10.1056/NEJMoa021641
pubmed: 12571259
Lacey CJ, Lowndes CM, Shah KV (2006) Burden and management of non -cancer HPV - related conditions: HPV-6/11 disease. Vaccine 24:S35–S41
doi: 10.1016/j.vaccine.2006.06.015
Juckett G, Hartman -Adams H (2010) Human papillomavirus: clinical manifestations and prevention. Am Family Phys 82:1209
Fehrmann F, Laimins LA (2003) Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22:5201–5207
doi: 10.1038/sj.onc.1206554
pubmed: 12910257
Aghakhani A, Hamkar R, Parvin M, Ghavami N, Nadri M, Pakfetrat A et al (2011) The role of human papillomavirus infection in prostate carcinoma. Scand J Infect Dis 43:64–69
doi: 10.3109/00365548.2010.502904
pubmed: 20662618
Chen AC-H, Waterboer T, Keleher A, Morrison B, Jindal S, McMillan D et al (2011) Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients. Pathol Oncol Res 17:613–617
doi: 10.1007/s12253-010-9357-4
pubmed: 21240663
Nasseri S, Monavari SH, Keyvani H, Nikkhoo B, Roudsari RV, Khazeni M (2015) The prevalence of human papilloma virus (HPV) infection in the oligospermic and azoospermic men. Med J Islam Repub Iran 29:272
pubmed: 26793663
pmcid: 4715409
Sadeghi F, Salehi-Vaziri M, Ghodsi SM, Alizadeh A, Bokhar - aei -Salim F, Saroukalaei ST et al (2015) Prevalence of JC polyoma - virus large T antigen sequences among iranian patients with central nervous system tumors. Arch Virol 160:61–68
doi: 10.1007/s00705-014-2230-0
pubmed: 25218012
Li N, Bi X, Zhang Y, Zhao P, Zheng T, Dai M (2011) Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis. Breast Cancer Res Treat 126:515–520
doi: 10.1007/s10549-010-1128-0
pubmed: 20740311
Abumsimir B, Mrabti M, Laraqui A, Ameur A, Koraishi SI, Mzibri, Ennaji MM (2022) Molecular characterization of human papillomavirus and mouse mammary tumor virus like infections in prostate cancer tissue and relevance with tumor features. Mol Clin Oncol 16(5):1–7
doi: 10.3892/mco.2022.2530
Fatemipour M, Nahand JS, Fard Azar ME, Baghi HB, Taghizadieh M, Sorayyayi S, Hussen BM, Mirzaei H, Moghoofei M, Bokharaei-Salim F (2020) Human papillomavirus and prostate cancer: the role of viral expressed proteins in the inhibition of anoikis and induction of metastasis. Microb Pathog 104576–. https://doi.org/10.1016/j.micpath.2020.104576
Khatami A, Nahand JS, Kiani SJ, Khoshmirsafa M, Moghoofei M, Khanaliha K, …, Bokharaei-Salim F (2022) Human papilloma virus (HPV) and prostate cancer (PCa): the potential role of HPV gene expression and selected cellular MiRNAs in PCa development. Microb Pathog 166:105503
doi: 10.1016/j.micpath.2022.105503
pubmed: 35398468
Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV et al (2019) Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra- deep sequencing of plasma cell -free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 37:1547–1557
doi: 10.1200/JCO.18.02052
pubmed: 31059311
Schøler LV, Reinert T, Orntoft MBW, Kassentoft CG, Arnadøttir SS, Vang S, Nordentoft I, Knudsen M, Lamy P, Andreasen D et al (2017) Clinical implications of circulating monitoring tumor DNA in patients with colorectal cancer. Clin. Cancer Res 23:5437–5445
Jakobsen KK, Carlander ALF, Bendtsen SK, Garset-Zamani M, Lynggaard CD, Grønhøj C, von Buchwald C (2021) Diagnostic accuracy of HPV detection in patients with Oropharyngeal squamous cell carcinomas: a systematic review and Meta- analysis. Viruses 13(9):1692
doi: 10.3390/v13091692
pubmed: 34578274
pmcid: 8473001
Kay P, Allan B, Denny L, Hoffman M, Williamson AL (2005) Detection of HPV 16 and HPV 18 DNA in the blood of patients with cervical cancer. J Med Virol 75(3):435–439
doi: 10.1002/jmv.20294
pubmed: 15648077
Kedzia H, Gozdzicka-Jozefiak A, Wolna M, Tomczak E (1992) Distribution of human papillomavirus 16 in the blood of women with uterine cervical cancer. Eur J Gynecol Oncol 13:522–526
Ho CM, Yang SS, Chien TY, Huang SH, Jeng CJ, Chang SF (2005) Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol Oncol 99(3):615–621
doi: 10.1016/j.ygyno.2005.07.004
pubmed: 16099020